title: Comparative evaluation of urinary PCA3 and TMPRSS2: ERG scores and serum PHI in predicting prostate cancer aggressiveness.
abstract: It has been suggested that urinary PCA3 and TMPRSS2:ERG fusion tests and serum PHI correlate to cancer aggressiveness-related pathological criteria at prostatectomy. To evaluate and compare their ability in predicting prostate cancer aggressiveness, PHI and urinary PCA3 and TMPRSS2:ERG (T2) scores were assessed in 154 patients who underwent radical prostatectomy for biopsy-proven prostate cancer. Univariate and multivariate analyses using logistic regression and decision curve analyses were performed. All three markers were predictors of a tumor volume≥0.5 mL. Only PHI predicted Gleason score≥7. T2 score and PHI were both independent predictors of extracapsular extension(≥pT3), while multifocality was only predicted by PCA3 score. Moreover, when compared to a base model (age, digital rectal examination, serum PSA, and Gleason sum at biopsy), the addition of both PCA3 score and PHI to the base model induced a significant increase (+12%) when predicting tumor volume>0.5 mL. PHI and urinary PCA3 and T2 scores can be considered as complementary predictors of cancer aggressiveness at prostatectomy.
authors: Medical Unit of Molecular Oncology and Transfer, Department of Biochemistry and Molecular Biology, University Hospital of Lyon Sud, Hospices Civils of Lyon, Chemin du Grand Revoyet, 69495 Pierre Bénite, France. lu.tallon@gmail.com.
authors: Lucile
authors: L
authors: Tallon
authors: Medical Unit of Molecular Oncology and Transfer, Department of Biochemistry and Molecular Biology, University Hospital of Lyon Sud, Hospices Civils of Lyon, Chemin du Grand Revoyet, 69495 Pierre Bénite, France. ldevillier@gmail.com.
authors: Devillier
authors: D
authors: Luangphakdy
authors: Department of Medicine and Pharmacy, Faculty of Lyon 1 University, 8 Avenue Rockefeller, 69373 Lyon, France. denis.champetier@chu-lyon.fr.
authors: Alain
authors: A
authors: Ruffion
authors: Department of Medicine and Pharmacy, Faculty of Lyon 1 University, 8 Avenue Rockefeller, 69373 Lyon, France. marc.colombel@chu-lyon.fr.
authors: Marc
authors: M
authors: Colombel
authors: Department of Medicine and Pharmacy, Faculty of Lyon 1 University, 8 Avenue Rockefeller, 69373 Lyon, France. marian.devonec@chu-lyon.fr.
authors: Marian
authors: M
authors: Devonec
authors: Department of Urology, University Hospital of Lyon Sud, Hospices Civils of Lyon, Chemin du Grand Revoyet, 69495 Pierre Bénite, France. denis.champetier@chu-lyon.fr.
authors: Denis
authors: D
authors: Champetier
authors: Department of Medicine and Pharmacy, Faculty of Lyon 1 University, 8 Avenue Rockefeller, 69373 Lyon, France. philippe.paparel@chu-lyon.fr.
authors: Philippe
authors: P
authors: Paparel
authors: Department of Medicine and Pharmacy, Faculty of Lyon 1 University, 8 Avenue Rockefeller, 69373 Lyon, France. myriam.decaussin-petrucci@chu-lyon.fr.
authors: Myriam
authors: M
authors: Decaussin-Petrucci
authors: Department of Medicine and Pharmacy, Faculty of Lyon 1 University, 8 Avenue Rockefeller, 69373 Lyon, France. paul.perrin@chu-lyon.fr.
authors: Paul
authors: P
authors: Perrin
authors: Medical Unit of Molecular Oncology and Transfer, Department of Biochemistry and Molecular Biology, University Hospital of Lyon Sud, Hospices Civils of Lyon, Chemin du Grand Revoyet, 69495 Pierre Bénite, France. virginie.vlaeminck-guillem@univ-lyon1.fr.
authors: Virginie
authors: V
authors: Vlaeminck-Guillem
mesh_terms: D000368:Aged; D000951:Antigens, Neoplasm / Q000652:urine*; D019540:Area Under Curve; D015415:Biomarkers / Q000652:urine; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010451:Peptide PHI / Q000097:blood*; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D012372:ROC Curve; D012697:Serine Endopeptidases / Q000652:urine*
chemical_list: D000951:Antigens, Neoplasm; D015415:Biomarkers; D010451:Peptide PHI; C479341:prostate cancer antigen 3, human; D012697:Serine Endopeptidases; C421305:TMPRSS2 protein, human; D017430:Prostate-Specific Antigen